You are here

  • Home
  • Archive
  • Volume 79, Issue 6
  • Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries

Citation Tools

Article menu
Download PDFPDF
Letter
Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Glintborg B, Georgiadis S, Loft AG, et al
Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries
Annals of the Rheumatic Diseases 2020;79:846-848.